Clinical Terminal
Funding & M&A

Windward Bio Raises $251.2M in Nasdaq IPO and Private Placement

Swiss biotech company Windward Bio has raised approximately $251.2 million through an initial public offering and a concurrent private placement, according to a report from investing.com.2

By Victoria Shi · AI Funding Reporter Nov 18, 2026

Windward Bio Raises $251.2M in Nasdaq IPO and Private Placement

The company began trading on the Nasdaq on Nov. 13, 2026, under the ticker symbol WWB, multiple outlets reported. The IPO consisted of 11,838,234 common shares priced at $17.00 per share, which included the full exercise of the underwriters' option to purchase additional shares, investing.com reported. Concurrently, Sanofi purchased $50 million in shares and pre-funded warrants in a private placement at the IPO price, according to reports from ThePharmaLetter and Endpoints News.2,4

Windward Bio, headquartered in Basel, Switzerland, focuses on developing treatments for inflammatory respiratory and dermatological diseases, according to several reports. The company's lead drug candidate is WIN378, a long-acting TSLP inhibitor licensed from China's Kelun-Biotech, pharmaphorum.com reported. The drug is in a Phase 2/3 trial for severe uncontrolled asthma and a Phase 2 trial for chronic obstructive pulmonary disease, the report said.3,4

The funds are intended to advance WIN378 into a second Phase 3 trial for asthma, Endpoints News reported.5

Windward Bio was launched in January 2025, according to ThePharmaLetter. Prior to the IPO, the company had raised $365 million in private funding, including a $200 million Series A round in January 2025 and a $165 million crossover financing in May 2026 led by OrbiMed, according to reports from ThePharmaLetter and multiples.vc. New investors in the May 2026 round included RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed, according to BioSpace and Harbour BioMed.4,6

Luca Santarelli is the founder, CEO and chairman of Windward Bio, according to his LinkedIn profile. Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank acted as joint book-running managers for the offering, investing.com reported.1,2